Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Clene Inc

CLNN ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$4.14

▼ -1.19%

Market Cap $52.90M · Vol 9.22K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$52.90M

Micro Cap

Div Yield

N/A

EPS Growth

+32.73%

YoY

RSI (14)

27.47

Momentum

Beta

0.94

vs Market

52W High

$13.29

68.85% below

52W Low

$3.53

17.28% above

Volume

9.22K

Avg 18.26K

P/B

N/A

Price-to-book

ROE

197.90%

Return on equity

Free Float

82.94%

Public shares

Shariah Compliance8 STANDARDS

✗ Clene Inc (CLNN) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CLNN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-21.59%

-33.12%

-41.28%

-2.13%

YTD

-29.47%

+15.00%

-72.21%

-97.58%

Financials & Valuation

TTM · Annual

Total Revenue	$200.00K
Net Income	$-26,173,000.00
Revenue Growth (YoY)	-40.74%
Gross Margin	78.50%
Operating Margin	-11,541.50%
Net Profit Margin	-13,086.50%
ROE	197.90%
ROA · ROIC	-115.13% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	289.36
P/B	N/A
P/FCF	N/A
EPS Growth	+32.73%
Outstanding Shares	12.78M

Technical Indicators

50-Day SMA	$5.59
200-Day SMA	$6.20
RSI (14)	27.47
Beta	0.94
52-Week High	$13.29
52-Week Low	$3.53

Volume Today	9.22K
Avg Daily Volume (30D)	18.26K
Relative Volume	0.50x
Volatility (10D)	90.17
Volatility (30D)	71.04
Free Float	82.94%

Analyst Consensus

BUY

Current Price $4.14

Mean Target $32.20

52W Low$3.53 52W High$13.29

Current

Target

$3.53 $13.29

Current Analyst target

+677.78% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00X3GTK84

ISINUS1856342019

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.